The global market for Hemostasis Diagnostics is estimated at US$2.3 Billion in 2023 and is projected to reach US$3.2 Billion by 2030, growing at a CAGR of 4.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. ![Hemostasis Diagnostics Market]( "Hemostasis Diagnostics Market")
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Prothrombin Test Time (PT) segment, which is expected to reach US$1.3 Billion by 2030 with a CAGR of a 4.6%. The D Dimer segment is also set to grow at 5.6% CAGR over the next 7 years.
- Regional Analysis: Gain insights into the U.S. market, estimated at $617.5 Million in 2023, and China, forecasted to grow at an impressive 8.4% CAGR to reach $736.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Hemostasis Diagnostics Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Hemostasis Diagnostics Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Hemostasis Diagnostics Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Abbott Laboratories, Alere, Inc., Danaher Corporation, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 46 Featured):
- Abbott Laboratories
- Alere, Inc.
- Danaher Corporation
- F. Hoffmann-La Roche AG
- Grifols SA
- Instrumentation Laboratory
- Nihon Kohden Corporation
- Siemens Healthineers
- Sysmex Corporation
- Thermo Fisher Scientific, Inc.
MarketGlass Platform
Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Hemostasis Diagnostics - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
- Global Economic Update
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 2: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 3: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 4: World Hemostasis Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- Table 5: World Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 6: World Historic Review for Hemostasis Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 7: World 16-Year Perspective for Hemostasis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
- Table 8: World Recent Past, Current & Future Analysis for Prothrombin Test Time (PT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 9: World Historic Review for Prothrombin Test Time (PT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 10: World 16-Year Perspective for Prothrombin Test Time (PT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 11: World Recent Past, Current & Future Analysis for D Dimer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 12: World Historic Review for D Dimer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 13: World 16-Year Perspective for D Dimer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 14: World Recent Past, Current & Future Analysis for Fibrinogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 15: World Historic Review for Fibrinogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 16: World 16-Year Perspective for Fibrinogen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 17: World Recent Past, Current & Future Analysis for Activated Partial Thromboplastin Time by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 18: World Historic Review for Activated Partial Thromboplastin Time by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 19: World 16-Year Perspective for Activated Partial Thromboplastin Time by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 22: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- Table 23: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 24: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 25: World 16-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
UNITED STATES
- Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- Table 26: USA Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 27: USA Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 28: USA 16-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2014, 2024 & 2030
- Table 29: USA Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 30: USA Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 31: USA 16-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2014, 2024 & 2030
CANADA
- Table 32: Canada Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 33: Canada Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 34: Canada 16-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2014, 2024 & 2030
- Table 35: Canada Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 36: Canada Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 37: Canada 16-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2014, 2024 & 2030
JAPAN
- Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- Table 38: Japan Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 39: Japan Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 40: Japan 16-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2014, 2024 & 2030
- Table 41: Japan Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 42: Japan Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 43: Japan 16-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2014, 2024 & 2030
CHINA
- Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- Table 44: China Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 45: China Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 46: China 16-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2014, 2024 & 2030
- Table 47: China Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 48: China Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 49: China 16-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2014, 2024 & 2030
EUROPE
- Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- Table 50: Europe Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 51: Europe Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 52: Europe 16-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2014, 2024 & 2030
- Table 53: Europe Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 54: Europe Historic Review for Hemostasis Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 55: Europe 16-Year Perspective for Hemostasis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
- Table 56: Europe Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 57: Europe Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 58: Europe 16-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2014, 2024 & 2030
FRANCE
- Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- Table 59: France Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 60: France Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 61: France 16-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2014, 2024 & 2030
- Table 62: France Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 63: France Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 64: France 16-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2014, 2024 & 2030
GERMANY
- Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- Table 65: Germany Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 66: Germany Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 67: Germany 16-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2014, 2024 & 2030
- Table 68: Germany Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 69: Germany Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 70: Germany 16-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2014, 2024 & 2030
ITALY
- Table 71: Italy Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 72: Italy Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 73: Italy 16-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2014, 2024 & 2030
- Table 74: Italy Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 75: Italy Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 76: Italy 16-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2014, 2024 & 2030
UNITED KINGDOM
- Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- Table 77: UK Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 78: UK Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 79: UK 16-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2014, 2024 & 2030
- Table 80: UK Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 81: UK Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 82: UK 16-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2014, 2024 & 2030
SPAIN
- Table 83: Spain Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 84: Spain Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 85: Spain 16-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2014, 2024 & 2030
- Table 86: Spain Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 87: Spain Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 88: Spain 16-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2014, 2024 & 2030
RUSSIA
- Table 89: Russia Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 90: Russia Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 91: Russia 16-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2014, 2024 & 2030
- Table 92: Russia Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 93: Russia Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 94: Russia 16-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2014, 2024 & 2030
REST OF EUROPE
- Table 95: Rest of Europe Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 96: Rest of Europe Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 97: Rest of Europe 16-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2014, 2024 & 2030
- Table 98: Rest of Europe Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 99: Rest of Europe Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 100: Rest of Europe 16-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2014, 2024 & 2030
ASIA-PACIFIC
- Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 102: Asia-Pacific Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 103: Asia-Pacific 16-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2014, 2024 & 2030
- Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 105: Asia-Pacific Historic Review for Hemostasis Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 106: Asia-Pacific 16-Year Perspective for Hemostasis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
- Table 107: Asia-Pacific Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 108: Asia-Pacific Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 109: Asia-Pacific 16-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2014, 2024 & 2030
AUSTRALIA
- Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
- Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
LATIN AMERICA
- Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
MIDDLE EAST
- Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
AFRICA
- Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Alere, Inc.
- Danaher Corporation
- F. Hoffmann-La Roche AG
- Grifols SA
- Instrumentation Laboratory
- Nihon Kohden Corporation
- Siemens Healthineers
- Sysmex Corporation
- Thermo Fisher Scientific, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 173 |
| Published | November 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 2.3 Billion |
| Forecasted Market Value ( USD | $ 3.2 Billion |
| Compound Annual Growth Rate | 4.8% |
| Regions Covered | Global |
